Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 8 of these applications claim priority to application PCT/US2013/045495, filed Jun 12, 2013. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,339,497 | Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan In force · High confidence | Ipsen Biopharm Ltd. | In force | High confidence | ||
| US 9,364,473 | Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan In force · Medium confidence | Ipsen Biopharm Ltd. | In force | Medium confidence | ||
| US 9,452,162 | Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan In force · Medium confidence | Ipsen Biopharm Ltd. | In force | Medium confidence | ||
| US 9,492,442 | Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan In force · Medium confidence | Ipsen Biopharm Ltd. | In force | Medium confidence | ||
| US 9,717,724 | Methods for Treating Pancreatic Cancer Using Combination Therapies In force · Low confidence | Ipsen Biopharm Ltd. | In force | Low confidence | ||
| US 10,980,795 | Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan In force · Medium confidence | Ipsen Biopharm Ltd. | In force | Medium confidence | ||
| US 11,369,597 | Methods For Treating Pancreatic Cancer Using Combination Therapies In force · Low confidence | Ipsen Biopharm Ltd. | In force | Low confidence | ||
| US 12,364,691 | Methods For Treating Pancreatic Cancer Using Combination Therapies In force · Low confidence | Ipsen Biopharm Ltd. | In force | Low confidence | ||
| Application 15/059,640 | Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan Abandoned Abandoned Jul 5, 2017 | Ipsen Biopharm Ltd. | Abandoned | Abandoned Jul 5, 2017 | ||
| Application 15/341,377 | Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan Abandoned Abandoned Nov 27, 2017 | Ipsen Biopharm Ltd. | Abandoned | Abandoned Nov 27, 2017 | ||
| 8 more patents in this group · Pro | ||||||
10 of 18 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 18.
8 of these are in force and held by Ipsen Biopharm Ltd..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.